Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis
- 주제(키워드) Febrile neutropenia , Lymphoma , non-Hodgkin , Elderly , Female , Albumin
- 주제(기타) Medicine, General & Internal
- 설명문(일반) [Kim, Yu Ri; Kim, Soo-Jeong; Kim, Jin Seok] Yonsei Univ, Severance Hosp, Coll Med, Dept Internal Med,Div Hematol, 50-1 Yonsei Ro, Seoul 03722, South Korea; [Park, Yong] Korea Univ, Med Ctr, Dept Internal Med, Seoul, South Korea; [Oh, Sung Yong] Dong A Univ, Coll Med, Dept Internal Med, Busan, South Korea; [Yun, Hwan-Jung] Chungnam Natl Univ, Coll Med, Dept Internal Med, Daejeon, South Korea; [Mun, Yeung-Chul] Ewha Womans Univ, Sch Med, Dept Internal Med, Seoul, South Korea
- 등재 SCIE, SCOPUS, KCI등재
- OA유형 gold, Green Published
- 발행기관 KOREAN ASSOC INTERNAL MEDICINE
- 발행년도 2021
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000183615
- 본문언어 영어
- Published As http://dx.doi.org/10.3904/kjim.2020.206
- PubMed https://pubmed.ncbi.nlm.nih.gov/34265889
초록/요약
Background/Aims: Febrile neutropenia (FN) interferes with the proper chemo-therapy dose density or intensity in non-Hodgkin's lymphoma (NHL) patients. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) +/- rituximab has an intermediate FN risk. Prophylactic granulocyte col-ony-stimulating factor (G-CSF) support is recommended for patients with other host-related risk factors. Methods: We evaluated the risk factors for FN-related admission in NHL patients who have received primary G-CSF (lenograstim) prophylaxis. Results: Data from 148 patients were analyzed. The incidence of neutropenic fe -ver was 96 events (12.2%), and the median period was 3.85 days (range, 0 to 5.9); the median duration of neutropenia was 4.21 days (range, 3.3 to 5.07). Eighty-three FN-related admissions were reported. Advanced age (> 60 years), female sex, a low albumin level, and prednisone use were associated with FN-related admission in multivariable analysis (p = 0.010, p < 0.001, and p = 0.010, respectively). A compar-ison between diffuse large B-cell lymphoma patients treated with R-CHOP and pegylated G-CSF and those treated with R-CHOP and lenograstim did not reveal significant differences in the FN-related admission rate between the two groups, although the lenograstim-treated group had a higher incidence of severe neutro-penia. Conclusions: Elderly patients, female patients, and patients with low albumin levels need to be actively followed-up for FN even when primary prophylaxis with G-CSF has been used.
more